Literature DB >> 25424423

Toll-like receptor 8 deletion accelerates autoimmunity in a mouse model of lupus through a Toll-like receptor 7-dependent mechanism.

Ngoc Lan Tran1, Céline Manzin-Lorenzi, Marie-Laure Santiago-Raber.   

Abstract

Systemic lupus erythematosus is an autoimmune disorder characterized by increased levels of lymphocyte activation, antigen presentation by dendritic cells, and the formation of autoantibodies. This leads to immune complex-mediated glomerulonephritis. Toll-like receptor 7 (T7) and TLR9 localize to the endosomal compartment and play important roles in the generation of autoantibodies against nuclear components, as they recognize RNA and DNA, respectively. In contrast, very little is known about endogenous TLR8 activation in mice. We therefore tested whether TLR8 could affect autoimmune responses in a murine model of lupus. We introduced a Tlr8 null mutation into C57BL/6 mice congenic for the Nba2 (NZB autoimmunity 2) locus and bearing the Yaa (Y-linked autoimmune acceleration) mutation containing a tlr8 duplicated gene, and monitored disease development, autoantibody production, and glomerulonephritis-associated mortality. Cellular responses were investigated in female Nba2.TLR8(-/-) mice bearing no copy of tlr8. The TLR8 deficiency accelerated disease progression and mortality, increased the number of circulating antibodies and activated monocytes, and heightened cellular responses to TLR7 ligation. TLR8-deficient antigen-presenting cells exhibited increased levels of MHC class II expression. The ability of dendritic cells to present antigens to allogeneic T cells after TLR7 ligation was also improved by TLR8 deficiency. TLR8 deletion accelerated autoimmunity in lupus-prone mice in response to TLR7 activation. Antigen-presenting cell function seemed to play a key role in mediating the effects of TLR8 deficiency.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  Toll-like receptors; monocytes; systemic lupus erythematosus

Mesh:

Substances:

Year:  2015        PMID: 25424423      PMCID: PMC4405324          DOI: 10.1111/imm.12426

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  47 in total

Review 1.  The use of laboratory tests in the diagnosis of SLE.

Authors:  W Egner
Journal:  J Clin Pathol       Date:  2000-06       Impact factor: 3.411

2.  T-bet regulates IgG class switching and pathogenic autoantibody production.

Authors:  Stanford L Peng; Susanne J Szabo; Laurie H Glimcher
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-16       Impact factor: 11.205

3.  Toll-like receptor 7-dependent loss of B cell tolerance in pathogenic autoantibody knockin mice.

Authors:  Robert Berland; Luis Fernandez; Elina Kari; Jin-Hwan Han; Ina Lomakin; Shizuo Akira; Henry H Wortis; John F Kearney; Angelo A Ucci; Thereza Imanishi-Kari
Journal:  Immunity       Date:  2006-09       Impact factor: 31.745

4.  Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus.

Authors:  Sean R Christensen; Jonathan Shupe; Kevin Nickerson; Michael Kashgarian; Richard A Flavell; Mark J Shlomchik
Journal:  Immunity       Date:  2006-09       Impact factor: 31.745

5.  Role of TLR9 in anti-nucleosome and anti-DNA antibody production in lpr mutation-induced murine lupus.

Authors:  Aurelia Lartigue; Philippe Courville; Isabelle Auquit; Arnaud François; Christophe Arnoult; François Tron; Daniele Gilbert; Philippe Musette
Journal:  J Immunol       Date:  2006-07-15       Impact factor: 5.422

6.  A Tlr7 translocation accelerates systemic autoimmunity in murine lupus.

Authors:  Srividya Subramanian; Katalin Tus; Quan-Zhen Li; Andrew Wang; Xiang-Hong Tian; Jinchun Zhou; Chaoying Liang; Guy Bartov; Lisa D McDaniel; Xin J Zhou; Roger A Schultz; Edward K Wakeland
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-15       Impact factor: 11.205

7.  Selective expansion of a monocyte subset expressing the CD11c dendritic cell marker in the Yaa model of systemic lupus erythematosus.

Authors:  Hirofumi Amano; Eri Amano; Marie-Laure Santiago-Raber; Thomas Moll; Eduardo Martinez-Soria; Liliane Fossati-Jimack; Masahiro Iwamoto; Stephen J Rozzo; Brian L Kotzin; Shozo Izui
Journal:  Arthritis Rheum       Date:  2005-09

8.  Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication.

Authors:  Prapaporn Pisitkun; Jonathan A Deane; Michael J Difilippantonio; Tatyana Tarasenko; Anne B Satterthwaite; Silvia Bolland
Journal:  Science       Date:  2006-05-18       Impact factor: 47.728

9.  Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus.

Authors:  Sean R Christensen; Michael Kashgarian; Lena Alexopoulou; Richard A Flavell; Shizuo Akira; Mark J Shlomchik
Journal:  J Exp Med       Date:  2005-07-18       Impact factor: 14.307

Review 10.  A pivotal role for the natural interferon alpha-producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus.

Authors:  L Rönnblom; G V Alm
Journal:  J Exp Med       Date:  2001-12-17       Impact factor: 14.307

View more
  12 in total

1.  TLR8 Couples SOCS-1 and Restrains TLR7-Mediated Antiviral Immunity, Exacerbating West Nile Virus Infection in Mice.

Authors:  Amber M Paul; Dhiraj Acharya; Linda Le; Penghua Wang; Dobrivoje S Stokic; A Arturo Leis; Lena Alexopoulou; Terrence Town; Richard A Flavell; Erol Fikrig; Fengwei Bai
Journal:  J Immunol       Date:  2016-10-21       Impact factor: 5.422

Review 2.  Toll-like receptors: potential targets for lupus treatment.

Authors:  Yan-wei Wu; Wei Tang; Jian-ping Zuo
Journal:  Acta Pharmacol Sin       Date:  2015-11-23       Impact factor: 6.150

Review 3.  Roles of B Cell-Intrinsic TLR Signals in Systemic Lupus Erythematosus.

Authors:  Kongyang Ma; Jingyi Li; Yongfei Fang; Liwei Lu
Journal:  Int J Mol Sci       Date:  2015-06-09       Impact factor: 5.923

Review 4.  Targeted therapeutics in SLE: emerging strategies to modulate the interferon pathway.

Authors:  Shereen Oon; Nicholas J Wilson; Ian Wicks
Journal:  Clin Transl Immunology       Date:  2016-05-13

Review 5.  Targeting the innate immune receptor TLR8 using small-molecule agents.

Authors:  Kentaro Sakaniwa; Toshiyuki Shimizu
Journal:  Acta Crystallogr D Struct Biol       Date:  2020-06-17       Impact factor: 7.652

6.  Human TLR8 Senses RNA From Plasmodium falciparum-Infected Red Blood Cells Which Is Uniquely Required for the IFN-γ Response in NK Cells.

Authors:  Christoph Coch; Benjamin Hommertgen; Thomas Zillinger; Juliane Daßler-Plenker; Bastian Putschli; Maximilian Nastaly; Beate M Kümmerer; Johanna F Scheunemann; Beatrix Schumak; Sabine Specht; Martin Schlee; Winfried Barchet; Achim Hoerauf; Eva Bartok; Gunther Hartmann
Journal:  Front Immunol       Date:  2019-03-27       Impact factor: 7.561

Review 7.  Beyond defense: regulation of neuronal morphogenesis and brain functions via Toll-like receptors.

Authors:  Chiung-Ya Chen; Yi-Chun Shih; Yun-Fen Hung; Yi-Ping Hsueh
Journal:  J Biomed Sci       Date:  2019-11-04       Impact factor: 8.410

Review 8.  Sex-based differences in inflammatory bowel diseases: a review.

Authors:  Sheila D Rustgi; Maia Kayal; Shailja C Shah
Journal:  Therap Adv Gastroenterol       Date:  2020-04-28       Impact factor: 4.409

9.  Expression and Functionality Study of 9 Toll-Like Receptors in 33 Drug-Naïve Non-Affective First Episode Psychosis Individuals: A 3-Month Study.

Authors:  Maria Juncal-Ruiz; Laura Riesco-Davila; Javier Vazquez-Bourgon; Victor Ortiz-Garcia de la Foz; Jacqueline Mayoral-Van Son; Rosa Ayesa-Arriola; Esther Setien-Suero; Juan Carlos Leza; Marcos Lopez-Hoyos; Benedicto Crespo-Facorro
Journal:  Int J Mol Sci       Date:  2020-08-25       Impact factor: 5.923

10.  Atherosclerotic plaque vulnerability is increased in mouse model of lupus.

Authors:  Marie-Laure Santiago-Raber; Fabrizio Montecucco; Nicolas Vuilleumier; Kapka Miteva; Daniela Baptista; Federico Carbone; Sabrina Pagano; Aline Roth; Fabienne Burger; Francois Mach; Karim J Brandt
Journal:  Sci Rep       Date:  2020-10-27       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.